Malin Corporation
plc
Poseida Therapeutics
Announces Research Collaboration and Licensing Agreement with
Astellas
Dublin-Ireland, 1
May 2024: Malin Corporation plc. (Euronext Growth
Dublin:MLC) (Malin), a company investing in highly innovative life
sciences companies, notes that its investee company, Poseida
Therapeutics, Inc. (Poseida), has announced that
it has entered into a research collaboration and licensing
agreement with Xyphos Biosciences Inc. (a wholly owned subsidiary
of Astellas Pharma Inc.) (Xyphos) to develop novel convertibleCAR® programs by combining
the innovative cell therapy platforms from each of the
companies.
Under the terms of the agreement,
the companies plan to combine Poseida's proprietary
allogeneic CAR-T platform with Xyphos' ACCEL™ technology to
create one Poseida-developed CAR-T construct to form the basis
of two convertibleCAR® product
candidates targeting solid tumours.
Xyphos will
reimburse Poseida for costs incurred as part of the
research agreement and will be responsible for the development and
future commercialisation of products generated from the
collaboration. Poseida will receive US $50
million upfront plus potential development and sales
milestones and contingency payments of up to US $550
million in total. Additionally, Poseida is eligible
for up to low double digit tiered royalties as a percentage of net
sales.
A copy of Poseida's press release is
available to view here:
Poseida Press Release 1 May 2024.
ENDS
About Malin Corporation plc
Malin (Euronext Growth Dublin:MLC)
is a company investing in highly innovative life sciences
companies. Its purpose is to create shareholder value through the
application of long-term capital and operational and strategic
expertise to a diverse range of global healthcare businesses. Malin
has a focus on innovative businesses underpinned by exceptional
science and works with its investee companies, providing strategic
and financial support to enable them to reach their value
potential. Malin is headquartered and domiciled in Ireland and
listed on the Euronext Growth Dublin. For more information
visit www.malinplc.com
For further
information please contact:
Malin
Fiona Dunlevy, Company
Secretary
Tel: +353 (0)1 901 5700
cosec@malinplc.com
Davy Corporate Finance (Euronext Growth Listing Sponsor &
Joint Broker)
Brian Garrahy / Daragh
O'Reilly
Tel: +353 1 679 6363
Liberum (Joint Broker)
Phil Walker / Ben Cryer
Tel: +44 (0) 20 3100 2000
Powerscourt (Media enquiries)
Eavan Gannon
Tel: +353 87 236 5973
malin@powerscourt-group.com